UFP Technologies, Inc. (UFPT) Stock Competitors & Peer Comparison

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, UFPT is priced at $215.02, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, UFPT's ROE is +0.17%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, UFPT is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check BSX-PA's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ABT has a market cap of 151.5B. Regarding current trading prices, UFPT is priced at $215.02, while ABT trades at $87.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ABT's P/E ratio is 24.36. In terms of profitability, UFPT's ROE is +0.17%, compared to ABT's ROE of +0.12%. Regarding short-term risk, UFPT is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check ABT's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ISRG has a market cap of 142.5B. Regarding current trading prices, UFPT is priced at $215.02, while ISRG trades at $400.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ISRG's P/E ratio is 48.76. In terms of profitability, UFPT's ROE is +0.17%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, UFPT is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check ISRG's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SYK has a market cap of 112.5B. Regarding current trading prices, UFPT is priced at $215.02, while SYK trades at $292.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SYK's P/E ratio is 34.00. In terms of profitability, UFPT's ROE is +0.17%, compared to SYK's ROE of +0.15%. Regarding short-term risk, UFPT is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check SYK's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, MDT has a market cap of 94.7B. Regarding current trading prices, UFPT is priced at $215.02, while MDT trades at $77.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas MDT's P/E ratio is 20.60. In terms of profitability, UFPT's ROE is +0.17%, compared to MDT's ROE of +0.10%. Regarding short-term risk, UFPT is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check MDT's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BSX has a market cap of 70.9B. Regarding current trading prices, UFPT is priced at $215.02, while BSX trades at $47.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BSX's P/E ratio is 19.95. In terms of profitability, UFPT's ROE is +0.17%, compared to BSX's ROE of +0.15%. Regarding short-term risk, UFPT is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check BSX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BRKRP has a market cap of 65B. Regarding current trading prices, UFPT is priced at $215.02, while BRKRP trades at $435.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BRKRP's P/E ratio is N/A. In terms of profitability, UFPT's ROE is +0.17%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, UFPT is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check BRKRP's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, EW has a market cap of 50.5B. Regarding current trading prices, UFPT is priced at $215.02, while EW trades at $86.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas EW's P/E ratio is 47.38. In terms of profitability, UFPT's ROE is +0.17%, compared to EW's ROE of +0.11%. Regarding short-term risk, UFPT is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check EW's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, DXCM has a market cap of 28.3B. Regarding current trading prices, UFPT is priced at $215.02, while DXCM trades at $72.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas DXCM's P/E ratio is 31.52. In terms of profitability, UFPT's ROE is +0.17%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, UFPT is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check DXCM's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, RMD has a market cap of 26.5B. Regarding current trading prices, UFPT is priced at $215.02, while RMD trades at $185.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas RMD's P/E ratio is 17.64. In terms of profitability, UFPT's ROE is +0.17%, compared to RMD's ROE of +0.24%. Regarding short-term risk, UFPT is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check RMD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, PHG has a market cap of 24.2B. Regarding current trading prices, UFPT is priced at $215.02, while PHG trades at $25.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas PHG's P/E ratio is 21.92. In terms of profitability, UFPT's ROE is +0.17%, compared to PHG's ROE of +0.09%. Regarding short-term risk, UFPT is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check PHG's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, STE has a market cap of 20.6B. Regarding current trading prices, UFPT is priced at $215.02, while STE trades at $210.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas STE's P/E ratio is 26.46. In terms of profitability, UFPT's ROE is +0.17%, compared to STE's ROE of +0.11%. Regarding short-term risk, UFPT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check STE's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, UFPT is priced at $215.02, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ABMD's P/E ratio is 65.36. In terms of profitability, UFPT's ROE is +0.17%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, UFPT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check ABMD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ZBH has a market cap of 16.2B. Regarding current trading prices, UFPT is priced at $215.02, while ZBH trades at $84.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ZBH's P/E ratio is 21.70. In terms of profitability, UFPT's ROE is +0.17%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, UFPT is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check ZBH's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, UFPT is priced at $215.02, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SWAV's P/E ratio is 78.76. In terms of profitability, UFPT's ROE is +0.17%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, UFPT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check SWAV's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, UFPT is priced at $215.02, while PEN trades at $318.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas PEN's P/E ratio is 73.60. In terms of profitability, UFPT's ROE is +0.17%, compared to PEN's ROE of +0.12%. Regarding short-term risk, UFPT is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check PEN's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SNN has a market cap of 12.5B. Regarding current trading prices, UFPT is priced at $215.02, while SNN trades at $29.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SNN's P/E ratio is 20.55. In terms of profitability, UFPT's ROE is +0.17%, compared to SNN's ROE of +0.12%. Regarding short-term risk, UFPT is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check SNN's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ALGN has a market cap of 11.9B. Regarding current trading prices, UFPT is priced at $215.02, while ALGN trades at $165.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ALGN's P/E ratio is 28.06. In terms of profitability, UFPT's ROE is +0.17%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, UFPT is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check ALGN's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, UFPT is priced at $215.02, while GMED trades at $77.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas GMED's P/E ratio is 18.29. In terms of profitability, UFPT's ROE is +0.17%, compared to GMED's ROE of +0.13%. Regarding short-term risk, UFPT is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check GMED's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, UFPT is priced at $215.02, while PODD trades at $142.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas PODD's P/E ratio is 33.28. In terms of profitability, UFPT's ROE is +0.17%, compared to PODD's ROE of +0.21%. Regarding short-term risk, UFPT is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check PODD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, UFPT is priced at $215.02, while MASI trades at $178.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas MASI's P/E ratio is 44.35. In terms of profitability, UFPT's ROE is +0.17%, compared to MASI's ROE of +0.09%. Regarding short-term risk, UFPT is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check MASI's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BRKR has a market cap of 8.7B. Regarding current trading prices, UFPT is priced at $215.02, while BRKR trades at $58.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BRKR's P/E ratio is -238.79. In terms of profitability, UFPT's ROE is +0.17%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, UFPT is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check BRKR's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BIO has a market cap of 8.3B. Regarding current trading prices, UFPT is priced at $215.02, while BIO trades at $304.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BIO's P/E ratio is 51.01. In terms of profitability, UFPT's ROE is +0.17%, compared to BIO's ROE of +0.02%. Regarding short-term risk, UFPT is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check BIO's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BIO-B has a market cap of 8.2B. Regarding current trading prices, UFPT is priced at $215.02, while BIO-B trades at $304.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BIO-B's P/E ratio is 50.64. In terms of profitability, UFPT's ROE is +0.17%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, UFPT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check BIO-B's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, GKOS has a market cap of 6.5B. Regarding current trading prices, UFPT is priced at $215.02, while GKOS trades at $111.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas GKOS's P/E ratio is -33.62. In terms of profitability, UFPT's ROE is +0.17%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, UFPT is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check GKOS's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, UFPT is priced at $215.02, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas NARI's P/E ratio is -59.24. In terms of profitability, UFPT's ROE is +0.17%, compared to NARI's ROE of -0.00%. Regarding short-term risk, UFPT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check NARI's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, UFPT is priced at $215.02, while LIVN trades at $71.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas LIVN's P/E ratio is 37.41. In terms of profitability, UFPT's ROE is +0.17%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, UFPT is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check LIVN's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, UFPT is priced at $215.02, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas AXNX's P/E ratio is -709.80. In terms of profitability, UFPT's ROE is +0.17%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, UFPT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check AXNX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, UFPT is priced at $215.02, while IRTC trades at $102.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas IRTC's P/E ratio is -124.12. In terms of profitability, UFPT's ROE is +0.17%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, UFPT is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check IRTC's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, UFPT is priced at $215.02, while ITGR trades at $90.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ITGR's P/E ratio is 22.37. In terms of profitability, UFPT's ROE is +0.17%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, UFPT is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check ITGR's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, UFPT is priced at $215.02, while TMDX trades at $67.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas TMDX's P/E ratio is 15.66. In terms of profitability, UFPT's ROE is +0.17%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, UFPT is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check TMDX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, UFPT is priced at $215.02, while AXGN trades at $39.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas AXGN's P/E ratio is -61.66. In terms of profitability, UFPT's ROE is +0.17%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, UFPT is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check AXGN's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, UFPT is priced at $215.02, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas NUVA's P/E ratio is 75.00. In terms of profitability, UFPT's ROE is +0.17%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, UFPT is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check NUVA's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, UFPT is priced at $215.02, while ESTA trades at $70.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ESTA's P/E ratio is -47.93. In terms of profitability, UFPT's ROE is +0.17%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, UFPT is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check ESTA's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, UFPT is priced at $215.02, while PRCT trades at $26.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas PRCT's P/E ratio is -14.62. In terms of profitability, UFPT's ROE is +0.17%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, UFPT is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check PRCT's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, UFPT is priced at $215.02, while AHCO trades at $9.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas AHCO's P/E ratio is -16.36. In terms of profitability, UFPT's ROE is +0.17%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, UFPT is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check AHCO's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, UFPT is priced at $215.02, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas HSKA's P/E ratio is -62.49. In terms of profitability, UFPT's ROE is +0.17%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, UFPT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check HSKA's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, UFPT is priced at $215.02, while TNDM trades at $18.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas TNDM's P/E ratio is -13.58. In terms of profitability, UFPT's ROE is +0.17%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, UFPT is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check TNDM's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, UFPT is priced at $215.02, while ENOV trades at $21.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ENOV's P/E ratio is -1.10. In terms of profitability, UFPT's ROE is +0.17%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, UFPT is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check ENOV's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, UFPT is priced at $215.02, while IART trades at $15.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas IART's P/E ratio is -2.42. In terms of profitability, UFPT's ROE is +0.17%, compared to IART's ROE of -0.48%. Regarding short-term risk, UFPT is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check IART's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, UFPT is priced at $215.02, while BFLY trades at $4.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BFLY's P/E ratio is -15.27. In terms of profitability, UFPT's ROE is +0.17%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, UFPT is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check BFLY's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, UFPT is priced at $215.02, while AVNS trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas AVNS's P/E ratio is -15.62. In terms of profitability, UFPT's ROE is +0.17%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, UFPT is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check AVNS's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, UFPT is priced at $215.02, while INSP trades at $39.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas INSP's P/E ratio is 9.23. In terms of profitability, UFPT's ROE is +0.17%, compared to INSP's ROE of +0.18%. Regarding short-term risk, UFPT is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check INSP's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, UFPT is priced at $215.02, while ATEC trades at $7.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ATEC's P/E ratio is -9.01. In terms of profitability, UFPT's ROE is +0.17%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, UFPT is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check ATEC's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, UFPT is priced at $215.02, while IRMD trades at $88.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas IRMD's P/E ratio is 49.10. In terms of profitability, UFPT's ROE is +0.17%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, UFPT is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check IRMD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, UFPT is priced at $215.02, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SILK's P/E ratio is -18.96. In terms of profitability, UFPT's ROE is +0.17%, compared to SILK's ROE of -0.35%. Regarding short-term risk, UFPT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check SILK's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, UFPT is priced at $215.02, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas FNA's P/E ratio is -19.83. In terms of profitability, UFPT's ROE is +0.17%, compared to FNA's ROE of -0.35%. Regarding short-term risk, UFPT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check FNA's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CNMD has a market cap of 1B. Regarding current trading prices, UFPT is priced at $215.02, while CNMD trades at $32.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CNMD's P/E ratio is 19.12. In terms of profitability, UFPT's ROE is +0.17%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, UFPT is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check CNMD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, AORT has a market cap of 991.5M. Regarding current trading prices, UFPT is priced at $215.02, while AORT trades at $20.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas AORT's P/E ratio is 81.70. In terms of profitability, UFPT's ROE is +0.17%, compared to AORT's ROE of +0.03%. Regarding short-term risk, UFPT is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check AORT's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, INMD has a market cap of 855.7M. Regarding current trading prices, UFPT is priced at $215.02, while INMD trades at $13.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas INMD's P/E ratio is 10.00. In terms of profitability, UFPT's ROE is +0.17%, compared to INMD's ROE of +0.13%. Regarding short-term risk, UFPT is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check INMD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, UFPT is priced at $215.02, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CSII's P/E ratio is -20.83. In terms of profitability, UFPT's ROE is +0.17%, compared to CSII's ROE of -0.14%. Regarding short-term risk, UFPT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check CSII's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SSII has a market cap of 797.5M. Regarding current trading prices, UFPT is priced at $215.02, while SSII trades at $4.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SSII's P/E ratio is -79.70. In terms of profitability, UFPT's ROE is +0.17%, compared to SSII's ROE of -0.23%. Regarding short-term risk, UFPT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check SSII's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, UFPT is priced at $215.02, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CRY's P/E ratio is 425.71. In terms of profitability, UFPT's ROE is +0.17%, compared to CRY's ROE of +0.03%. Regarding short-term risk, UFPT is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check CRY's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, LMRI has a market cap of 721.6M. Regarding current trading prices, UFPT is priced at $215.02, while LMRI trades at $7.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas LMRI's P/E ratio is -19.26. In terms of profitability, UFPT's ROE is +0.17%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, UFPT is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check LMRI's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CBLL has a market cap of 663.2M. Regarding current trading prices, UFPT is priced at $215.02, while CBLL trades at $17.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CBLL's P/E ratio is -10.79. In terms of profitability, UFPT's ROE is +0.17%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, UFPT is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check CBLL's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SIBN has a market cap of 621.3M. Regarding current trading prices, UFPT is priced at $215.02, while SIBN trades at $13.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SIBN's P/E ratio is -35.92. In terms of profitability, UFPT's ROE is +0.17%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, UFPT is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check SIBN's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, UFPT is priced at $215.02, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SRDX's P/E ratio is -34.66. In terms of profitability, UFPT's ROE is +0.17%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, UFPT is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check SRDX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, UFPT is priced at $215.02, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas APEN's P/E ratio is -9.43. In terms of profitability, UFPT's ROE is +0.17%, compared to APEN's ROE of -0.85%. Regarding short-term risk, UFPT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check APEN's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BWAY has a market cap of 571.1M. Regarding current trading prices, UFPT is priced at $215.02, while BWAY trades at $13.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BWAY's P/E ratio is 66.18. In terms of profitability, UFPT's ROE is +0.17%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, UFPT is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check BWAY's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, NPCE has a market cap of 555.4M. Regarding current trading prices, UFPT is priced at $215.02, while NPCE trades at $15.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas NPCE's P/E ratio is -25.06. In terms of profitability, UFPT's ROE is +0.17%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, UFPT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check NPCE's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, TCMD has a market cap of 550.6M. Regarding current trading prices, UFPT is priced at $215.02, while TCMD trades at $23.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas TCMD's P/E ratio is 28.06. In terms of profitability, UFPT's ROE is +0.17%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, UFPT is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check TCMD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BVS has a market cap of 549.4M. Regarding current trading prices, UFPT is priced at $215.02, while BVS trades at $8.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BVS's P/E ratio is 19.78. In terms of profitability, UFPT's ROE is +0.17%, compared to BVS's ROE of +0.16%. Regarding short-term risk, UFPT is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check BVS's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CTKB has a market cap of 541.1M. Regarding current trading prices, UFPT is priced at $215.02, while CTKB trades at $4.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CTKB's P/E ratio is -7.22. In terms of profitability, UFPT's ROE is +0.17%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, UFPT is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check CTKB's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CERS has a market cap of 541M. Regarding current trading prices, UFPT is priced at $215.02, while CERS trades at $2.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CERS's P/E ratio is -54.00. In terms of profitability, UFPT's ROE is +0.17%, compared to CERS's ROE of -0.15%. Regarding short-term risk, UFPT is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check CERS's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, UFPT is priced at $215.02, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, UFPT's ROE is +0.17%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, UFPT is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check ZIMV's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, PACB has a market cap of 490.8M. Regarding current trading prices, UFPT is priced at $215.02, while PACB trades at $1.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas PACB's P/E ratio is -3.85. In terms of profitability, UFPT's ROE is +0.17%, compared to PACB's ROE of -4.88%. Regarding short-term risk, UFPT is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check PACB's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, LAB has a market cap of 452.8M. Regarding current trading prices, UFPT is priced at $215.02, while LAB trades at $1.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas LAB's P/E ratio is -8.92. In terms of profitability, UFPT's ROE is +0.17%, compared to LAB's ROE of -0.21%. Regarding short-term risk, UFPT is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check LAB's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, KIDS has a market cap of 431.8M. Regarding current trading prices, UFPT is priced at $215.02, while KIDS trades at $17.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas KIDS's P/E ratio is -10.01. In terms of profitability, UFPT's ROE is +0.17%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, UFPT is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check KIDS's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, PMI has a market cap of 429M. Regarding current trading prices, UFPT is priced at $215.02, while PMI trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas PMI's P/E ratio is -0.36. In terms of profitability, UFPT's ROE is +0.17%, compared to PMI's ROE of +4.99%. Regarding short-term risk, UFPT is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check PMI's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, VREX has a market cap of 418.5M. Regarding current trading prices, UFPT is priced at $215.02, while VREX trades at $9.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas VREX's P/E ratio is -4.97. In terms of profitability, UFPT's ROE is +0.17%, compared to VREX's ROE of -0.18%. Regarding short-term risk, UFPT is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check VREX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, OFIX has a market cap of 392.5M. Regarding current trading prices, UFPT is priced at $215.02, while OFIX trades at $9.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas OFIX's P/E ratio is -6.47. In terms of profitability, UFPT's ROE is +0.17%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, UFPT is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check OFIX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CLPT has a market cap of 371M. Regarding current trading prices, UFPT is priced at $215.02, while CLPT trades at $12.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CLPT's P/E ratio is -12.37. In terms of profitability, UFPT's ROE is +0.17%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, UFPT is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check CLPT's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, DCTH has a market cap of 363.5M. Regarding current trading prices, UFPT is priced at $215.02, while DCTH trades at $10.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas DCTH's P/E ratio is 1053.00. In terms of profitability, UFPT's ROE is +0.17%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, UFPT is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check DCTH's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, VMD has a market cap of 363.4M. Regarding current trading prices, UFPT is priced at $215.02, while VMD trades at $9.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas VMD's P/E ratio is 25.62. In terms of profitability, UFPT's ROE is +0.17%, compared to VMD's ROE of +0.11%. Regarding short-term risk, UFPT is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check VMD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, AVR has a market cap of 341.8M. Regarding current trading prices, UFPT is priced at $215.02, while AVR trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas AVR's P/E ratio is -4.18. In terms of profitability, UFPT's ROE is +0.17%, compared to AVR's ROE of -1.24%. Regarding short-term risk, UFPT is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check AVR's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, MASS has a market cap of 334.7M. Regarding current trading prices, UFPT is priced at $215.02, while MASS trades at $8.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas MASS's P/E ratio is -9.12. In terms of profitability, UFPT's ROE is +0.17%, compared to MASS's ROE of -0.26%. Regarding short-term risk, UFPT is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check MASS's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, UFPT is priced at $215.02, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SMLR's P/E ratio is 3.92. In terms of profitability, UFPT's ROE is +0.17%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, UFPT is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check SMLR's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ELMD has a market cap of 305.3M. Regarding current trading prices, UFPT is priced at $215.02, while ELMD trades at $36.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ELMD's P/E ratio is 31.51. In terms of profitability, UFPT's ROE is +0.17%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, UFPT is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check ELMD's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SENS has a market cap of 286.6M. Regarding current trading prices, UFPT is priced at $215.02, while SENS trades at $6.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SENS's P/E ratio is -3.48. In terms of profitability, UFPT's ROE is +0.17%, compared to SENS's ROE of -1.30%. Regarding short-term risk, UFPT is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check SENS's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CATX has a market cap of 276.2M. Regarding current trading prices, UFPT is priced at $215.02, while CATX trades at $3.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CATX's P/E ratio is -2.54. In terms of profitability, UFPT's ROE is +0.17%, compared to CATX's ROE of -0.42%. Regarding short-term risk, UFPT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check CATX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, UFPT is priced at $215.02, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas MGRM's P/E ratio is -11.11. In terms of profitability, UFPT's ROE is +0.17%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, UFPT is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check MGRM's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SGHT has a market cap of 236.7M. Regarding current trading prices, UFPT is priced at $215.02, while SGHT trades at $4.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SGHT's P/E ratio is -6.21. In terms of profitability, UFPT's ROE is +0.17%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, UFPT is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check SGHT's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, TMCI has a market cap of 225.1M. Regarding current trading prices, UFPT is priced at $215.02, while TMCI trades at $3.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas TMCI's P/E ratio is -3.61. In terms of profitability, UFPT's ROE is +0.17%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, UFPT is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check TMCI's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, UFPT is priced at $215.02, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas NVRO's P/E ratio is -1.91. In terms of profitability, UFPT's ROE is +0.17%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, UFPT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check NVRO's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, UFPT is priced at $215.02, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas EYES's P/E ratio is N/A. In terms of profitability, UFPT's ROE is +0.17%, compared to EYES's ROE of -2.64%. Regarding short-term risk, UFPT is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check EYES's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, RXST has a market cap of 204.5M. Regarding current trading prices, UFPT is priced at $215.02, while RXST trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas RXST's P/E ratio is -4.37. In terms of profitability, UFPT's ROE is +0.17%, compared to RXST's ROE of -0.17%. Regarding short-term risk, UFPT is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check RXST's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, PROF has a market cap of 196.1M. Regarding current trading prices, UFPT is priced at $215.02, while PROF trades at $6.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas PROF's P/E ratio is -5.23. In terms of profitability, UFPT's ROE is +0.17%, compared to PROF's ROE of -0.71%. Regarding short-term risk, UFPT is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check PROF's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, ANIK has a market cap of 191.3M. Regarding current trading prices, UFPT is priced at $215.02, while ANIK trades at $14.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas ANIK's P/E ratio is -18.20. In terms of profitability, UFPT's ROE is +0.17%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, UFPT is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check ANIK's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, UFPT is priced at $215.02, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas BSGM's P/E ratio is -5.81. In terms of profitability, UFPT's ROE is +0.17%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, UFPT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check BSGM's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, EDAP has a market cap of 179.1M. Regarding current trading prices, UFPT is priced at $215.02, while EDAP trades at $4.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas EDAP's P/E ratio is -5.83. In terms of profitability, UFPT's ROE is +0.17%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, UFPT is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check EDAP's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, UFPT is priced at $215.02, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas MDGS's P/E ratio is -0.27. In terms of profitability, UFPT's ROE is +0.17%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, UFPT is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check MDGS's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, QTRX has a market cap of 165.1M. Regarding current trading prices, UFPT is priced at $215.02, while QTRX trades at $3.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas QTRX's P/E ratio is -1.49. In terms of profitability, UFPT's ROE is +0.17%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, UFPT is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check QTRX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, INGN has a market cap of 164.9M. Regarding current trading prices, UFPT is priced at $215.02, while INGN trades at $6.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas INGN's P/E ratio is -6.69. In terms of profitability, UFPT's ROE is +0.17%, compared to INGN's ROE of -0.13%. Regarding short-term risk, UFPT is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check INGN's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, UFPT is priced at $215.02, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas QIPT's P/E ratio is -15.87. In terms of profitability, UFPT's ROE is +0.17%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, UFPT is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for UFPT.Check QIPT's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, APYX has a market cap of 161.2M. Regarding current trading prices, UFPT is priced at $215.02, while APYX trades at $3.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas APYX's P/E ratio is -17.50. In terms of profitability, UFPT's ROE is +0.17%, compared to APYX's ROE of -0.91%. Regarding short-term risk, UFPT is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check APYX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, CVRX has a market cap of 144M. Regarding current trading prices, UFPT is priced at $215.02, while CVRX trades at $5.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas CVRX's P/E ratio is -2.70. In terms of profitability, UFPT's ROE is +0.17%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, UFPT is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check CVRX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, NNOX has a market cap of 133.6M. Regarding current trading prices, UFPT is priced at $215.02, while NNOX trades at $1.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas NNOX's P/E ratio is -1.66. In terms of profitability, UFPT's ROE is +0.17%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, UFPT is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check NNOX's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, MXCT has a market cap of 131.8M. Regarding current trading prices, UFPT is priced at $215.02, while MXCT trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas MXCT's P/E ratio is -3.42. In terms of profitability, UFPT's ROE is +0.17%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, UFPT is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check MXCT's competition here

UFPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UFPT stands at 1.7B. In comparison, SNWV has a market cap of 129.8M. Regarding current trading prices, UFPT is priced at $215.02, while SNWV trades at $15.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UFPT currently has a P/E ratio of 24.68, whereas SNWV's P/E ratio is 15.73. In terms of profitability, UFPT's ROE is +0.17%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, UFPT is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for UFPT.Check SNWV's competition here